Journal Articles

The following is a list of peer-reviewed journal articles pertaining to the microbiota-based products currently under development in the MRT™ drug platform. Click on the title to view complete information.

RBX2660 for Recurrent Clostridium difficile Infection

Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic

Ken F. Blount, William D. Shannon, Elena Deych, and Courtney Jones

RBX2660 for Recurrent Clostridium difficile Infection

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-based Drug Targeted at Recurrent Clostridium difficile Infection

Erik R. Dubberke, Kathleen M. Mullane, Dale N. Gerding, Christine H. Lee, Thomas J. Louie, Harriet Guthertz, and Courtney Jones

Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study

Robert Orenstein, Erik Dubberke, Robert Hardi, Arnab Ray, Kathleen Mullane, Darrell S. Pardi, and Mayur S. Ramesh; for the PUNCH CD Investigators